US 11059906
Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11059906 (Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma) held by Takeda Pharmaceutical Company Limited expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545